Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Not yet recruiting 3Unknown 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 9Gynecologic 5Gastrointestinal 5Thoracic 4Other solid neoplasm 2Head & Neck 2Genitourinary 2Dermatologic 2Sarcoma 1NET 1Endocrine 1

Conditions

Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Recurrence 1Endometrial Neoplasms 1Cervical Cancer Metastatic 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × famitinib × Gynecologic × Clear all
NCT07382713 2026-02-03

Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer

The First Affiliated Hospital of Soochow University

Phase 2 Not yet recruiting
43 enrolled
Gynecologic

Ovarian Neoplasms

NCT07355010 2026-01-21

A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer

Tongji Hospital

Phase 2 Not yet recruiting
104 enrolled
Gynecologic

Ovarian Neoplasms

NCT07143292 2025-11-18

A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
120 enrolled
Gynecologic

Cervical Cancer Metastatic

NCT04680988 2025-08-05

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
194 enrolled
Gynecologic

Uterine Cervical Neoplasms, Recurrence

NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
265 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡